Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and oth…
$1.51+7.86%
报价 2026-11-06
市值
$28.8M
EV
$27.7M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -89.8%
$1.40$14.85
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ELTXElicio Therapeutics, Inc. | $28.8M | +7.9% | +769.6% | 0% | – | – | – | |
| PEPGPepGen Inc. | $170.8M | +6.5% | +837.5% | 0% | – | – | – | |
| NKTXNkarta, Inc. | $123.9M | +10.2% | – | 0% | – | – | – | |
| MOLNMolecular Partners AG | $119.7M | -2.5% | – | 0% | – | – | – | |
| MISTMilestone Pharmaceuticals Inc. | $95M | +10.2% | – | 94.6% | – | – | – | |
| CRDFCardiff Oncology, Inc. | $61.9M | +5.3% | -40.0% | 100% | – | – | – | |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $59.4M | +7.3% | 0.0% | 0% | – | – | – | |
| RANIRani Therapeutics Holdings, Inc. | $35.7M | +5.9% | -13.5% | 96.7% | – | – | – | |
| ACTUActuate Therapeutics Inc | $7.9M | +0.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -6.7% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。